Targeting CBP/p300 Overcomes Acquired Vincristine Resistance in Medulloblastoma

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Medulloblastoma is the most common malignant pediatric brain tumor. Although advances in conventional therapies have improved survival over the years, acquired drug resistance remains a major barrier to durable cure. As dysregulation of epigenetic mechanisms is increasingly recognized as a driver of medulloblastoma pathogenesis and therapeutic adaptation, targeting epigeneti...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• CREB-Binding Protein
• E1A-Associated p300 Protein
• Enzyme Inhibitors
• Mutation
• Neoplasms
• p300-CBP Transcription Factors
• Protein Degradation and Inhibitors

Identifiers and source

Literature Corpus work

659477a7-490d-5f50-9e48-bc3ee1fcfad0

DOI

10.64898/2026.07.28.740967